Login to Your Account

Erytech Takes Lead on TEDAC with Investment, Technology

By Nuala Moran
Staff Writer

Wednesday, June 13, 2012
LONDON – Erytech Pharma is to lead a €21 million (US$26.2 million) project to develop enzyme therapies that attack cancers by depleting amino acids in the tumor environment that are essential for tumor growth, and will also discover biomarkers to identify patients who are likely to respond to those treatments.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription